---
title: "Ergotamine - Migraine"
sidebar: mydoc_sidebar
permalink: db00696-mesh-d008881-1.html
toc: false 
---


Path ID: `DB00696_MESH_D008881_1`
{% include image.html url="images/db00696-mesh-d008881-1.png" file="db00696-mesh-d008881-1.png" alt="db00696-mesh-d008881-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D004878">MESH:D004878 </a> | ergotamine | Drug |
| <a href="https://identifiers.org/UniProt:P28221">UniProt:P28221 </a> | 5-hydroxytryptamine receptor 1D | Protein |
| <a href="https://identifiers.org/UniProt:P35348">UniProt:P35348 </a> | Alpha-1A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P08913">UniProt:P08913 </a> | Alpha-2A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18825">UniProt:P18825 </a> | Alpha-2C adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P25100">UniProt:P25100 </a> | Alpha-1D adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P35368">UniProt:P35368 </a> | Alpha-1B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18089">UniProt:P18089 </a> | Alpha-2B adrenergic receptor | Protein |
| <a href="https://identifiers.org/MESH:D013373">MESH:D013373 </a> | Substance P | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0006954">GO:0006954 </a> | inflammatory response | BiologicalProcess |
| <a href="https://identifiers.org/GO:0042310">GO:0042310 </a> | vasoconstriction | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D008881">MESH:D008881 </a> | Migraine | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Ergotamine | POSITIVELY REGULATES | Alpha-1A Adrenergic Receptor |
| Ergotamine | POSITIVELY REGULATES | Alpha-2A Adrenergic Receptor |
| Ergotamine | POSITIVELY REGULATES | Alpha-2C Adrenergic Receptor |
| Ergotamine | POSITIVELY REGULATES | Alpha-1D Adrenergic Receptor |
| Ergotamine | POSITIVELY REGULATES | Alpha-1B Adrenergic Receptor |
| Ergotamine | POSITIVELY REGULATES | Alpha-2B Adrenergic Receptor |
| Alpha-1A Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-2A Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-2C Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-1D Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-1B Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-2B Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Vasoconstriction | NEGATIVELY CORRELATED WITH | Migraine |
| Ergotamine | POSITIVELY REGULATES | 5-Hydroxytryptamine Receptor 1D |
| 5-Hydroxytryptamine Receptor 1D | POSITIVELY REGULATES | Vasoconstriction |
| 5-Hydroxytryptamine Receptor 1D | DECREASES ABUNDANCE OF | Substance P |
| Substance P | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Migraine |
|---------|-----------|---------|

Reference: 
  - [https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2095203/](https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2095203/)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/8223#section=Mechanism-of-Action](https://pubchem.ncbi.nlm.nih.gov/compound/8223#section=Mechanism-of-Action)
  - [https://en.wikipedia.org/wiki/Migraine#Management](https://en.wikipedia.org/wiki/Migraine#Management)
